Drug class profile · refreshed daily from federal data

Interleukin-31 Receptor alpha Antagonist

1 molecule in this class, $94.1M combined CY2024 Part D spend across 15K claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Interleukin-31 Receptor alpha Antagonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $94.1Mcombined across class
Total Rx claims: 15K5K unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Nemolizumab-Ilto

Brand: NEMLUVIO · 15K Part D claims (CY24) · 5K beneficiaries · First FDA approval: 2024-08-13

Brand-only (no generics) 57 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $94.1M

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.